Minocycline Development for Acute Ischemic Stroke

Translational Stroke Research

Volumn 2, Issue 2, 2011, Pages 202-208

  Fagan, Susan C ^a,b,c   Cronic, Lydia E ^a   Hess, David C ^a,c  

^a UNIVERSITY OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Acute stroke; Drug development; Minocycline; Vascular protection

Indexed keywords

MINOCYCLINE; TISSUE PLASMINOGEN ACTIVATOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIPOPHILICITY; NEUROPROTECTION; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 79955729003     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-011-0072-6     Document Type: Article

References (50)

1. Matsukawa N, Yasuhara T, Hara K, Xu L, Maki M, Yu G, et al. Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci. 2009; 10(1): 126.
2. Kleindorfer D, Xu Y, Moomaw CJ, Khatri P, Adeoye O, Hornung R. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke. 2009; 40(11): 3580-4.
3. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988; 15(6): 355-66.
4. Coskey R. Acne: treatment with minocycline. Cutis. 1976; 17(4): 799-801.
5. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 122(2): 81-9.
6. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA. 1998; 95(26): 15769-74.
7. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA. 1999; 96(23): 13496-500.
8. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett. 2001; 315(1-2): 61-4.
9. Zhu S, Stavrovskaya IG, Drozda M, Kim BYS, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002; 417(6884): 74-8. doi: 10. 1038/417074a.
10. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001; 21(8): 2580-8.
11. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 2001; 909(1-2): 187-93.
12. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002; 22(5): 1763-71.
13. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001; 48(6): 1393-401.
14. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci. 2006; 103(25): 9685-90.
15. Machado L, Kozak A, Ergul A, Hess D, Borlongan C, Fagan S. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006; 7(1): 56.
16. Elewa H, Hilali H, Hess D, Machado L, Fagan S. Minocycline for short-term neuroprotection. Pharmacotherapy. 2006; 26(4): 15-21.
17. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA. 2001; 98(25): 14669-74.
18. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000; 6(7): 797-801. doi: 10. 1038/77528.
19. Wang C, Yang T, Noor R, Shuaib A. Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol. 2002; 2(1): 2.
20. Arvin KL, Han BH, Du Y, Lin S-Z, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002; 52(1): 54-61.
21. Wang CX, Yang T, Shuaib A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res. 2003; 963(1-2): 327-9.
22. Wells JEA, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain. 2003; 126(7): 1628-37.
23. Power C, Henry S, Del Bigio MR, Larsen PH, Corbett D, Imai Y, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol. 2003; 53(6): 731-42.
24. Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J, et al. Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat-effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res. 2008; 1188: 198-206.
25. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003; 53(2): 267-70.
26. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler Jr. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003; 60(8): 1234-40.
27. Kim H-S, Suh Y-H. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009; 196(2): 168-79.
28. Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, et al. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson disease (NET-PD) experience. Arch Neurol. 2009; 66(9): 1099-104.
29. Gordon PH, Gelinas DF, Qualls C, Meister ME, Werner J, Mendoza M, et al. Placebo controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology. 2004; 62(10): 1845-7.
30. Xu L, Fagan SC, Waller J, Edwards D, Borlongan C, Zheng J, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004; 4(1): 7.
31. Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke. 2010; 41(10): 2283-7.
32. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Mishima S, Fujioka M, et al. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke. 2008; 39(3): 951-8.
33. Liu Z, Fan Y, Won SJ, Neumann M, Hu D, Zhou L, et al. Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke. 2007; 38(1): 146-52.
34. Hewlett KA, Corbett D. Delayed minocycline treatment reduces long-term functional deficits and histological injury in a rodent model of focal ischemia. Neuroscience. 2006; 141(1): 27-33.
35. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocycline treatment in acute stroke. Neurology. 2007; 69(14): 1404-10.
36. Wang J, Wei Q, Wang C-Y, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem. 2004; 279(19): 19948-54.
37. Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B. 2003; 791(1-2): 337-43.
38. Drew TM, Altman R, Black K, Goldfield M. Minocycline for prophylaxis of infection with Neisseria meningitidis: high rate of side effects in recipients. J Infect Dis. 1976; 133(2): 194-8.
39. Clark BJ, Dornbush AC, Hutchinson J. Minocycline administered intravenously: pharmacological activity and clinical experience. Curr Ther Res. 1974; 16(9): 865-77.
40. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke; Journal Cerebral Circulation. 2008; 39(12): 3372-7.
41. Machado LS, Sazonova IY, Kozak A, Wiley DC, El-Remessy AB, Ergul A, et al. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke. 2009; 40(9): 3028-33.
42. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston Jr LL, del Zoppo GJ. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke. 2004; 35(4): 998-1004.
43. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab. 1996; 16(3): 360-6.
44. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral Ischemia. J Cereb Blood Flow Metab. 1999; 19(6): 624-33.
45. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin J-C, Kawase M, Massengale J, et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab. 1999; 19(9): 1020-8.
46. Weng YC, Kriz J. Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia. Exp Neurol. 2007; 204(1): 433-42.
47. Sathasivam S, Grierson AJ, Shaw PJ. Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition. Neuropathol Appl Neurobiol. 2005; 31(5): 467-85.
48. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006; 5(7): 603-12.
49. Tilley BC, Marler J, Geller NL, Lu M, Legler J, Brott T, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke. 1996; 27(11): 2136-42.
50. Li J, McCullough LD. Sex differences in minocycline-induced neuroprotection after experimental stroke. J Cereb Blood Flow Metab. 2009; 29(4): 670-4.